MEDIPOST

Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

MEDIPOST

South Korea

medipost_logoMEDIPOST has dedicated its focus on biotechnology from its foundation in year 2000 until today, in spite of numerous adversities, rises and falls within the stem cell area.

As a result, MEDIPOST has become a frontrunner in the field of the biopharmaceuticals not only in Korea but also in the world. MEDIPOST with its state-of-the-art platform technology has led to the development and approval of the world’s first allogeneic stem cell therapy product – CARTISTEM®.

MEDIPOST continues its endeavors on clinical development and commercialization of stem cell therapeutics to improve quality of lives of many patients with intractable diseases not only in Korea, but also around the globe.

Contact Details:

21, Daewangpangyo-ro 644 (Sampyeong-dong), Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

MEDIPOST Co., Ltd. CEO Yang, Yoon Sun

Business Registration No.: 211-86-61218

TEL : 82-2-3465-6650 / FAX : 82-2-3465-6688

http://twitter.com/medi_post

http://www.medi-post.com/

filterProfiles

Find a company:







Jobs from Indeed
LATEST ISSUE

DOWNLOAD


X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: